

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities of the Company.

*This announcement is not for distribution, directly or indirectly, in or into the United States. This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The Company's shares mentioned in this announcement have not been and will not be registered under the United States Securities Act of 1933, as amended (the "**Securities Act**") and may not be offered or sold in the United States except pursuant to registration or an exemption from the registration requirements of the Securities Act. No public offering of the Company's shares will be made in the United States.*



CONCORD HEALTHCARE GROUP CO., LTD.

美中嘉和醫學技術發展集團股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2453)

COMPLETION OF THE ISSUE OF CONVERTIBLE BONDS UNDER GENERAL MANDATE

Placing Agent



Reference is made to the announcement of Concord Healthcare Group Co., Ltd. (美中嘉和醫學技術發展集團股份有限公司) (the "**Company**") dated 11 May 2026 (the "**Announcement**") in relation to the proposed issue of the Bonds. Unless otherwise defined, all terms used herein shall have the same meanings as those defined in the Announcement.

The Board is pleased to announce that all the conditions precedent under the Placing and Subscription Agreement have been fulfilled and the issue of the Bonds in an aggregate principal amount of HK\$68 million was completed on 13 May 2026.

ADJUSTMENT EVENTS TO THE CONVERSION PRICE

As disclosed in the subsection headed "Adjustments to Conversion Price" under the section headed "**THE PRINCIPAL TERMS AND CONDITIONS OF THE BONDS**" in the Announcement, the Conversion Price is subject to the adjustment events numbered (1) to (10). All adjustment events relating to the Conversion Price are within the control of the Company, and the Company does not anticipate taking any actions that would result in the number of Conversion Shares exceeding the limit of the General Mandate.

In the event that the number of Conversion Shares to be issued would exceed the limit on the allotment and issue of Shares under the General Mandate due to an adjustment to the Conversion Price, the Company intends to allot and issue the excess Conversion Shares under the general mandate granted by the Shareholders at the annual general meeting of the Company held on 11 May 2026, pursuant to which the Directors were authorised to issue, allot and/or deal with additional Domestic and/or H Shares in the share capital of the Company not exceeding 20% of the total number of Shares in issue as at the date of passing the resolution, being 156,732,403 Shares.

EFFECT ON SHAREHOLDING STRUCTURE OF THE COMPANY

As at the date of this announcement, the total number of issued Shares of the Company is 783,662,016 Shares, of which 313,874,624 Shares are H Shares of RMB1.00 each and 469,787,392 Shares are Domestic Shares of RMB1.00 each.

The table below sets out a summary of (i) the shareholding structure of the Company as at the date of this announcement; and (ii) the shareholding structure of the Company assuming the Bonds are fully converted into Conversion Shares at the initial Conversion Price of HK\$1.7 per Share, on the assumption that there will be no other change to the share capital of the Company:

Name of Shareholders	(i) As at the date of this announcement		(ii) Assuming all the Bonds are fully issued and converted into Conversion Shares at the initial Conversion Price of HK\$1.7 per Share	
	Number of Shares	Approximate percentage of total issued Shares (%)	Number of Shares	Approximate percentage of total issued Shares (%)
Domestic Shares				
Core connected persons (<i>Note 1</i>)	390,052,412	49.77	390,052,412	47.36
CSPC Group (<i>Note 2</i>)	28,195,488	3.60	28,195,488	3.42
Other Domestic Shareholders	51,539,492	10.17	51,539,492	6.26
Sub-total	469,787,392	59.95	469,787,392	57.04
H Shares				
Subscriber	–	–	40,000,000	4.86
Core connected persons (<i>Note 3</i>)	63,859,100	8.15	63,859,100	7.75
Other H Shareholders	250,015,524	31.90	250,015,524	30.35
Sub-total	313,874,624	40.05	353,874,624	42.96
Total	783,662,016	100.00	823,662,016	100.00

Notes:

1. This represents the sum of (i) 192,274,636 Domestic Shares that Dr. Yang Jianyu, our chairman of the Board, is deemed to be interested; (ii) 120,000,000 Domestic Shares that CICC Jiatai Phase II (Tianjin) Equity Investment Fund Partnership (Limited Partnership) (中金佳泰貳期(天津)股權投資基金合夥企業(有限合夥)) is interested; and (iii) 77,777,776 Domestic Shares that Ningbo Xinyu Jiahui Enterprise Management Co., Ltd. (寧波信鈺嘉慧企業管理有限公司) is interested.
2. As at the date of this announcement, CSPC NBP Pharmaceutical Co., Ltd. (石藥集團恩必普藥業有限公司), a wholly-owned subsidiary of CSPC Group and an affiliate of the Subscriber, holds 28,195,488 Domestic Shares (representing approximately 3.60% of the total share capital of the Company). Assuming full conversion of the Bonds into Conversion Shares at the initial Conversion Price of HK\$1.7 per Share, CSPC Group and its subsidiaries will hold 28,195,488 Domestic Shares and 40,000,000 H Shares (representing approximately 8.28% of the total share capital of the Company).
3. This represents 63,859,100 H Shares that Dr. Yang Jianyu, our chairman of the Board, is deemed to be interested.
4. The sum of the shareholding percentage may not be equal to the total percentage due to rounding.

By order of the Board
Concord Healthcare Group Co., Ltd.
YANG Jianyu
Chairman of the Board and Executive Director

Beijing, the PRC, 13 May 2026

As at the date of this announcement, the Board comprises (i) Dr. YANG Jianyu, and Mr. JIANG Wei as executive Directors; (ii) Mr. WANG Lei, Mr. SONG Qingbao and Mr. SHI Botao as non-executive Directors; (iii) Ms. LI Xuemei, Mr. SUN Yansheng and Mr. NG Kwok Yin as independent non-executive Directors; and (iv) Ms. JIANG Li as employee Director.